Status:
COMPLETED
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Acute Undifferentiated Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Eligibility:
All Genders
Phase:
NA
Brief Summary
This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia. Diagnostic procedures, such as bioelectrical impedance...
Detailed Description
PRIMARY OBJECTIVES: I: To determine the feasibility of obtaining standardized phase angle measurements (bioelectrical impedance measurement) on patients hospitalized for treatment of newly diagnosed ...
Eligibility Criteria
Inclusion
- Hospitalized for newly diagnosed acute leukemia
- Receiving induction treatment while hospitalized
- Willing and able to provide written informed consent
Exclusion
- Presence of a pacemaker or defibrillator
- Patients pregnant at the time of enrollment
- Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
- Unable/unwilling to follow protocol requirements
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2020
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01869777
Start Date
July 1 2013
End Date
May 1 2020
Last Update
August 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States, 27157